Literature DB >> 33219206

Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia.

Prateek Pophali1, Aasiya Matin1, Abhishek A Mangaonkar1, Ryan Carr1, Moritz Binder1, Aref Al-Kali1, Kebede H Begna1, Kaaren K Reichard2, Hassan Alkhateeb1, Mithun V Shah1, Ayalew Tefferi1, William J Hogan1, Mark R Litzow1, Mrinal M Patnaik3.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 33219206      PMCID： PMC7679455          DOI： 10.1038/s41408-020-00387-y

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN： 2044-5385            Impact factor:   11.037


× No keyword cloud information.
  14 in total

1.  Blast transformation in chronic myelomonocytic leukemia: Risk factors, genetic features, survival, and treatment outcome.

Authors:  Mrinal M Patnaik; Emnet A Wassie; Terra L Lasho; Curtis A Hanson; Rhett Ketterling; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2015-04-01       Impact factor: 10.047

2.  An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.

Authors:  Michael R Savona; Luca Malcovati; Rami Komrokji; Ramon V Tiu; Tariq I Mughal; Attilio Orazi; Jean-Jacques Kiladjian; Eric Padron; Eric Solary; Raoul Tibes; Raphael Itzykson; Mario Cazzola; Ruben Mesa; Jaroslaw Maciejewski; Pierre Fenaux; Guillermo Garcia-Manero; Aaron Gerds; Guillermo Sanz; Charlotte M Niemeyer; Francisco Cervantes; Ulrich Germing; Nicholas C P Cross; Alan F List
Journal:  Blood       Date:  2015-01-26       Impact factor: 22.113

Review 3.  Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2018-06       Impact factor: 10.047

4.  Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia.

Authors:  M A Elliott; A Tefferi; W J Hogan; L Letendre; D A Gastineau; S M Ansell; A Dispenzieri; M A Gertz; S R Hayman; D J Inwards; M Q Lacy; I N Micallef; L F Porrata; M R Litzow
Journal:  Bone Marrow Transplant       Date:  2006-06       Impact factor: 5.483

5.  Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.

Authors:  Hesham Eissa; Ted A Gooley; Mohamed L Sorror; Franchesca Nguyen; Bart L Scott; Kristine Doney; Keith R Loeb; Paul J Martin; John M Pagel; Jerry P Radich; Brenda M Sandmaier; E Houston Warren; Rainer Storb; Frederick R Appelbaum; H Joachim Deeg
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-06       Impact factor: 5.742

6.  Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Authors:  Nicolaus Kröger; Tatjana Zabelina; Philipe Guardiola; Volker Runde; Jorge Sierra; Anja Van Biezen; Dietger Niederwieser; Axel R Zander; Theo De Witte
Journal:  Br J Haematol       Date:  2002-07       Impact factor: 6.998

7.  Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Argiris Symeonidis; Anja van Biezen; Liesbeth de Wreede; Alfonso Piciocchi; Juergen Finke; Dietrich Beelen; Martin Bornhäuser; Jan Cornelissen; Liisa Volin; Ghulam Mufti; Yves Chalandon; Arnold Ganser; Benedetto Bruno; Dietger Niederwieser; Guido Kobbe; Rainer Schwerdtfeger; Theo de Witte; Marie Robin; Nicolaus Kröger
Journal:  Br J Haematol       Date:  2015-07-26       Impact factor: 6.998

Review 8.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

9.  ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.

Authors:  M M Patnaik; R Itzykson; T L Lasho; O Kosmider; C M Finke; C A Hanson; R A Knudson; R P Ketterling; A Tefferi; E Solary
Journal:  Leukemia       Date:  2014-04-03       Impact factor: 11.528

10.  Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.

Authors:  Jane Merlevede; Nathalie Droin; Tingting Qin; Kristen Meldi; Kenichi Yoshida; Margot Morabito; Emilie Chautard; Didier Auboeuf; Pierre Fenaux; Thorsten Braun; Raphael Itzykson; Stéphane de Botton; Bruno Quesnel; Thérèse Commes; Eric Jourdan; William Vainchenker; Olivier Bernard; Noemie Pata-Merci; Stéphanie Solier; Velimir Gayevskiy; Marcel E Dinger; Mark J Cowley; Dorothée Selimoglu-Buet; Vincent Meyer; François Artiguenave; Jean-François Deleuze; Claude Preudhomme; Michael R Stratton; Ludmil B Alexandrov; Eric Padron; Seishi Ogawa; Serge Koscielny; Maria Figueroa; Eric Solary
Journal:  Nat Commun       Date:  2016-02-24       Impact factor: 14.919
View more
  6 in total

1.  Prognostic implication of early minimal residual disease evaluation in patients with chronic myelomonocytic leukemia.

Authors:  Lulu Wang; Rongrong Chen; Li Li; Lixia Zhu; Xianbo Huang; Xiujin Ye
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

Review 2.  Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms.

Authors:  Laura Palomo; Pamela Acha; Francesc Solé
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

3.  How I diagnose and treat chronic myelomonocytic leukemia.

Authors:  Mrinal M Patnaik
Journal:  Haematologica       Date:  2022-07-01       Impact factor: 11.047

Review 4.  Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders.

Authors:  Argiris Symeonidis; Spiros Chondropoulos; Evgenia Verigou; Vasileios Lazaris; Alexandra Kourakli; Panagiotis Tsirigotis
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

5.  Real-World Data on Chronic Myelomonocytic Leukemia: Clinical and Molecular Characteristics, Treatment, Emerging Drugs, and Patient Outcomes.

Authors:  Sandra Castaño-Díez; Mónica López-Guerra; Cristina Bosch-Castañeda; Alex Bataller; Paola Charry; Daniel Esteban; Francesca Guijarro; Carlos Jiménez-Vicente; Carlos Castillo-Girón; Albert Cortes; Alexandra Martínez-Roca; Ana Triguero; José Ramón Álamo; Silvia Beà; Dolors Costa; Dolors Colomer; María Rozman; Jordi Esteve; Marina Díaz-Beyá
Journal:  Cancers (Basel)       Date:  2022-08-25       Impact factor: 6.575

Review 6.  Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).

Authors:  Jan Philipp Bewersdorf; Amer M Zeidan
Journal:  Cancers (Basel)       Date:  2021-03-31       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.